Published October 2018 | Version v1
Journal article

Nrf2 in alcoholic liver disease

  • 1. Program of Environmental Toxicology, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, Liaoning 110122 (China)
  • 2. Group of Chronic Disease and Environmental Genomics, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, Liaoning 110122 (China)

Description

Highlights: • The Keap1-Nrf2 stress response pathway protects ALD from oxidative stress. • Nrf2 is involved in the regulation of lipid metabolism in ALD. • Nrf2 may be implicated in the progression of ALD, paradoxically. Alcoholic liver disease (ALD) is a leading cause of morbidity and mortality of liver disorders and a major health issue globally. ALD refers to a spectrum of liver pathologies ranging from steatosis, steatohepatitis, fibrosis, cirrhosis and even hepatocellular carcinoma. Various mechanisms, including oxidative stress, protein and DNA modification, inflammation and impaired lipid metabolism, have been implicated in the pathogenesis of ALD. Further, reactive oxygen species (ROS) in particular, have been identified as a key component in the initiation and progression of ALD. Nuclear factor erythroid 2 like 2 (Nrf2) is a master regulator of the intracellular adaptive antioxidant response to oxidative stress, and aids in the detoxification of a variety of toxicants. Given its cytoprotective role, Nrf2 has been extensively studied as a therapeutic target for ALD. Paradoxically, however, emerging evidence have revealed that Nrf2 may be implicated in the progression of ALD. In this review, we summarize the role of Nrf2 in the development of ALD and discuss the underlying mechanisms. Clearly, more comprehensive studies with proper animal and cell models and in human are needed to verify the potential therapeutic role of Nrf2 in ALD.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.taap.2018.08.019

Additional details

Identifiers

DOI
10.1016/j.taap.2018.08.019;
PII
S0041008X18303867;

Publishing Information

Journal Title
Toxicology and Applied Pharmacology
Journal Volume
357
Journal Page Range
p. 62-69
ISSN
0041-008X
CODEN
TXAPA9

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
54106876
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
AIDS; DNA; FIBROSIS; HEPATOMAS; INFLAMMATION; LIPIDS; LIVER; METABOLISM
Descriptors DEC
BODY; CARCINOMAS; DIGESTIVE SYSTEM; DISEASES; GLANDS; IMMUNE SYSTEM DISEASES; INFECTIOUS DISEASES; NEOPLASMS; NUCLEIC ACIDS; ORGANIC COMPOUNDS; ORGANS; PATHOLOGICAL CHANGES; SYMPTOMS; VIRAL DISEASES; ZOONOTIC DISEASES

Optional Information

Copyright
Copyright (c) 2018 Elsevier Inc. All rights reserved.